A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer

Huifang Zong(Shanghai Jiao Tong University), Jianwei Zhu(Shanghai Jiao Tong University)
Acta Pharmacologica Sinica
April 11, 2024
10.1038/s41401-024-01279-8
Cited by 29

Related Papers

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
|Journal of Nanobiotechnology|2022|66
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
|Journal of Experimental & Clinical Cancer Research|2020|62
RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis
|Frontiers in Oncology|2020|53
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
|Cell Discovery|2022|24